Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director comp.
Consulting agrmnt
Appointed COO
Appointed director
CC transcript
|
|
MOMENTA PHARMACEUTICALS INC (MNTA)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/01/2020 |
GN
| Momenta Pharmaceuticals Announces Completion of Proposed Sale to Johnson & Johnson |
| 09/16/2020 |
GN
| Bragar Eagel & Squire, P.C. Reminds Investors that it is Investigating the Boards of Directors of Rosetta Stone, Momenta, Jernigan, and Varian on behalf of Stockholders and Encourages Investors to Contact the Firm |
| 09/15/2020 |
GN
| Momenta Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period in Connection with Proposed Sale to Johnson & Johnson |
| 09/01/2020 |
GN
| Lifshitz Law Firm, P.C. Announces Investigation of Cancer Genetics, Inc., Momenta Pharmaceuticals, Inc., Principia Biopharma Inc., and Yintech Investment Holdings Limited |
| 08/19/2020 |
GN
| MOMENTA PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Buyout |
| 08/19/2020 |
GN
| Momenta Enters Definitive Agreement with Johnson & Johnson |
| 08/03/2020 |
GN
| Momenta Pharmaceuticals Announces Date of Second Quarter 2020 Financial Results Conference Call and Webcast |
| 07/28/2020 |
GN
| Momenta Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Nipocalimab in HDFN |
| 06/15/2020 |
GN
| Momenta Pharmaceuticals Announces Positive Topline Data from Interim Analysis of Phase 2 Vivacity-MG Study of Nipocalimab (M281) in Generalized Myasthenia Gravis (gMG) |
| 05/07/2020 |
GN
| Momenta Pharmaceuticals Reports First Quarter 2020 Financial and Operating Results |
| 04/02/2020 |
GN
| Momenta Provides Corporate Update Amid COVID-19 Pandemic |
| 02/26/2020 |
GN
| Momenta Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results |
| 01/13/2020 |
GN
| Momenta Provides Year-End 2019 Update and 2020 Outlook |
| 01/03/2020 |
GN
| Momenta Pharmaceuticals Announces CFO Transition |
| 12/13/2019 |
GN
| Momenta Pharmaceuticals Appoints Dr. Jane F. Barlow to Board of Directors |
| 12/12/2019 |
GN
| Momenta Pharmaceuticals Announces Pricing of Public Offering of Common Stock |
| 12/10/2019 |
GN
| Momenta Pharmaceuticals Announces Proposed Public Offering of Common Stock |
| 11/06/2019 |
GN
| Momenta Pharmaceuticals to Webcast Presentation at Two Upcoming Investor Conferences |
| 10/31/2019 |
GN
| Momenta Pharmaceuticals Reports Third Quarter 2019 Financial and Operating Results |
| 07/19/2019 |
GN
| Momenta Pharmaceuticals Announces Date of Second Quarter 2019 Financial Results Conference Call and Webcast |
| 06/04/2019 |
GN
| Momenta Pharmaceuticals to Webcast Presentation at the Goldman Sachs 40th Annual Global Healthcare Conference |
| 05/09/2019 |
GN
| Momenta Pharmaceuticals to Webcast Presentation at the 2019 Bank of America Merrill Lynch Healthcare Conference |
| 05/02/2019 |
GN
| Momenta Pharmaceuticals Reports First Quarter 2019 Financial and Operating Results |
| 03/29/2019 |
GN
| New Research Coverage Highlights American International Group, Fox Factory Holding, Momenta Pharmaceuticals, Mercer International, Endurance International Group, and Addus HomeCare — Consolidated Revenues, Company Growth, and Expectations for 2019 |
| 03/28/2019 |
GN
| Momenta Pharmaceuticals Announces Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2019 |
| 03/21/2019 |
GN
| Momenta Pharmaceuticals Announces Publication of New Data Supporting M281 as First Anti-FcRn Antibody to Inhibit Maternal-Fetal IgG Transfer in the Human Term Placenta |
| 02/22/2019 |
GN
| Momenta Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results |
| 02/08/2019 |
GN
| Momenta Pharmaceuticals Announces Date of Fourth Quarter and Year End 2018 Financial Results Conference Call and Webcast |
| 02/07/2019 |
GN
| Momenta Pharmaceuticals Announces Oral Presentation of New Data for M281 at the Society for Maternal-Fetal Medicine 2019 Annual Meeting |
| 12/11/2018 |
GN
| Momenta Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriter's Option to Purchase Additional Shares |
| 12/06/2018 |
GN
| UPDATE: Momenta Pharmaceuticals Announces Pricing of Public Offering of Common Stock |
| 12/06/2018 |
GN
| Momenta Pharmaceuticals Announces Pricing of Public Offering of Common Stock |
| 12/05/2018 |
GN
| Momenta Pharmaceuticals Announces Proposed Public Offering of Common Stock |
| 12/03/2018 |
GN
| Momenta Pharmaceuticals Provides Update on US Regulatory Strategy for M923, Proposed Biosimilar to HUMIRA® |
|
|
|